Premier Biomedical Inc (BIEI) financial statements (2020 and earlier)

Company profile

Business Address P.O. BOX 25
JACKSON CENTER, PA 16133
State of Incorp. NV
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments 8784223510316
Cash and cash equivalents 8784223510316
Receivables 30 37  
Inventory, net of allowances, customer advances and progress billings 2685   
Inventory 2685    
Prepaid expense   11996
Other current assets 4435    
Other undisclosed current assets    (16)3 
Total current assets: 160204346711622
Noncurrent Assets
Property, plant and equipment 555454
Total noncurrent assets: 555454
TOTAL ASSETS: 165209397012125
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities 286353239196147122
Accounts payable 264347221188147122
Interest and dividends payable 226188  
Debt 310170303015109
Due to related parties 26418285  
Other undisclosed current liabilities 1,6902,256348362643
Total current liabilities: 2,3122,820700347188275
Noncurrent Liabilities
Total liabilities: 2,3122,820700347188275
Stockholders' equity
Stockholders' equity attributable to parent, including: (2,147)(2,611)(661)(276)(68)(249)
Preferred stock 222   
Common stock 063100
Additional paid in capital 14,57313,43611,90010,5018,1286,536
Accumulated deficit (16,728)(16,329)(12,565)(10,778)(8,196)(6,785)
Other undisclosed stockholders' equity attributable to parent 5274    
Total stockholders' equity: (2,147)(2,611)(661)(276)(68)(249)
TOTAL LIABILITIES AND EQUITY: 165209397012125

Income statement (P&L) ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Revenues 4040 10  
Net investment income    10  
Cost of revenue (114)(25)    
Cost of goods and services sold (88)(25)    
Gross profit: (74)14 10  
Operating expenses (619)(1,304)(638)(2,383)(1,369)(4,477)
Other undisclosed operating loss    (10)  
Operating loss: (693)(1,290)(638)(2,383)(1,369)(4,477)
Nonoperating income (expense) 294(2,474)(1,130)(199)(42)(400)
Interest and debt expense (415)(352)(817)(199)(42)(400)
Loss before gain (loss) on sale of properties: (814)(4,115)(2,586)(2,781)(1,452)(5,278)
Other undisclosed net income    19942400
Net loss: (814)(4,115)(2,586)(2,582)(1,411)(4,877)
Other undisclosed net income attributable to parent 415352817   
Net loss available to common stockholders, diluted: (399)(3,764)(1,768)(2,582)(1,411)(4,877)

Comprehensive Income ($ in thousands)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
12/31/2013
Net loss: (814)(4,115)(2,586)(2,582)(1,411)(4,877)
Comprehensive loss, net of tax, attributable to parent: (814)(4,115)(2,586)(2,582)(1,411)(4,877)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: